Investor Relations
Financial Reporting
Filings and Reports
SEC Filings
Quarterly & Annual Reports
Sustainability
Disclosures
GAAP to Non-GAAP Reconciliation
Resources
Investor FAQs
Email Alerts Subscription
Newsroom
About Myriad
Corporate information
Corporate Governance
Executive Team
Myriad Milestones
Latest events
Events & Presentations
Investor Day
Contact Us
NASDAQ:
MYGN
$4.43
1.14%
DAY HIGH
$5.71
YEAR HIGH
$14.73
DAY LOW
$4.38
YEAR LOW
$3.76
02/24/2026
Search:
NASDAQ:
MYGN
$4.43
1.14%
Search:
Investor Relations
Financial Reporting
Filings and Reports
SEC Filings
Quarterly & Annual Reports
Sustainability
Disclosures
GAAP to Non-GAAP Reconciliation
Resources
Investor FAQs
Email Alerts Subscription
Newsroom
About Myriad
Corporate information
Corporate Governance
Executive Team
Myriad Milestones
Latest events
Events & Presentations
Investor Day
Contact Us
News Releases
Select year
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Categories
All Categories
Corporate
Products
Pipeline
Financial
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
Feb 24, 2026 | Products
Read more
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Feb 19, 2026 | Products
Read more
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
Jan 27, 2026 | Products
Read more